Roth/MKM Starts Unity Bio (UBX) at Buy

(Updated - May 30, 2023 4:35 PM EDT)

Roth/MKM analyst Dylan Dupuls initiates coverage on UNITY Biotechnology (NASDAQ: UBX) with a Buy rating and a price target of $10.00.

The analyst comments "We are initiating coverage on UBX at Buy, $10 PT based on the potential for lead agent UBX1325 in degenerative eye diseases. UBX1325 is a potential first-in-class senolytic agent that could disrupt the standard of care in DME and nAMD, first targeting anti-VEGF experienced DME patients that represents a niche yet significant market opportunity given the large patient population. Approval in this indication could open the door to larger and earlier lines of treatment in nAMD and DME, and in combination with anti-VEGF treatments."

You May Also Be Interested In

• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating